I-Mab announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the company's board of directors. Dr. Ruyi He will serve on the compensation committee and Professor Shao will serve on the corporate governance committee both effective Junes 1, 2021. Dr. Ruyi He is the Chief Medical Officer (CMO) of RemeGen Inc. and Venture Partner of SDIC Fund Management Co., the former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). He joined the NMPA in 2016, after having worked at the U.S. Food and Drug Administration (FDA) for almost two decades. As the first overseas expert hired by NMPA as the Chief Scientist, Dr. He organized and led many NMPA reforms on the drug evaluation system. In addition to establishing guidance for drug evaluation and approvals in China, Dr. He has also introduced multiple international policies into the NMPA, including conditional approval and acceptance of clinical data from abroad.